VVUS - VIVUS, Inc.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
0.472
-0.003 (-0.632%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close0.475
Open0.480
Bid0.000 x 0
Ask0.000 x 0
Day's Range0.452 - 0.481
52 Week Range0.450 - 1.380
Volume598,655
Avg. Volume718,917
Market Cap50.01M
Beta0.45
PE Ratio (TTM)1.39
EPS (TTM)0.339
Earnings DateMar 6, 2018 - Mar 12, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.50
Trade prices are not sourced from all markets
  • Marketwired23 days ago

    VIVUS Announces Change in Leadership

    VIVUS, Inc. today announced that it has reached agreement with Seth H. Z. Fischer pursuant to which he will step down as chief executive officer and a member of the board of directors effective December ...

  • Capital Cube28 days ago

    ETFs with exposure to VIVUS, Inc. : December 22, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to VIVUS, Inc. Here are 5 ETFs with the largest exposure to VVUS-US. Comparing the performance and risk of VIVUS, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Capital Cube2 months ago

    ETFs with exposure to VIVUS, Inc. : December 1, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to VIVUS, Inc. Here are 5 ETFs with the largest exposure to VVUS-US. Comparing the performance and risk of VIVUS, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Capital Cube2 months ago

    ETFs with exposure to VIVUS, Inc. : November 20, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to VIVUS, Inc. Here are 5 ETFs with the largest exposure to VVUS-US. Comparing the performance and risk of VIVUS, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of VVUS earnings conference call or presentation 7-Nov-17 9:30pm GMT

    Q3 2017 VIVUS Inc Earnings Call

  • Capital Cube2 months ago

    ETFs with exposure to VIVUS, Inc. : November 10, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to VIVUS, Inc. Here are 5 ETFs with the largest exposure to VVUS-US. Comparing the performance and risk of VIVUS, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • VIVUS (VVUS) Q3 Loss Narrows, Qsymia Falters, Shares Down
    Zacks2 months ago

    VIVUS (VVUS) Q3 Loss Narrows, Qsymia Falters, Shares Down

    VIVUS (VVUS) reported third-quarter results wherein it reported narrower-than- expected loss. However, Qsymia sales fell from the year-ago period.

  • VIVUS, Inc. :VVUS-US: Earnings Analysis: Q3, 2017 By the Numbers : November 9, 2017
    Capital Cube2 months ago

    VIVUS, Inc. :VVUS-US: Earnings Analysis: Q3, 2017 By the Numbers : November 9, 2017

    Categories: Yahoo FinanceGet free summary analysis VIVUS, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of VIVUS, Inc. – Apricus Biosciences, Inc., Pfizer Inc., Cardinal Health, Inc., Eli Lilly and Company, AmerisourceBergen Corporation and Arena Pharmaceuticals, Inc. (APRI-US, PFE-US, CAH-US, LLY-US, ABC-US and ARNA-US) that ... Read more (Read more...)

  • Marketwired2 months ago

    VIVUS Reports Third Quarter 2017 Financial Results

    VIVUS, Inc. , a biopharmaceutical company committed to the development and commercialization of innovative therapies focusing on treatments for patients with serious unmet medical needs, today reported ...

  • ACCESSWIRE2 months ago

    VIVUS, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / November 7, 2017 / VIVUS, Inc. (NASDAQ: VVUS ) will be discussing their earnings results in their Q3 Earnings Call to be held on November 7, 2017 at 4:30 PM Eastern Time. To ...

  • Marketwired3 months ago

    VIVUS Completes Tacrolimus Pre-IND Meeting With FDA

    VIVUS, Inc. , a biopharmaceutical company committed to the development and commercialization of innovative therapies focusing on treatments for patients with serious unmet medical needs, today announced ...

  • Capital Cube3 months ago

    ETFs with exposure to VIVUS, Inc. : October 30, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to VIVUS, Inc. Here are 5 ETFs with the largest exposure to VVUS-US. Comparing the performance and risk of VIVUS, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • VIVUS, Inc. :VVUS-US: Earnings Analysis: Q2, 2017 By the Numbers : October 6, 2017
    Capital Cube3 months ago

    VIVUS, Inc. :VVUS-US: Earnings Analysis: Q2, 2017 By the Numbers : October 6, 2017

    Categories: Yahoo FinanceGet free summary analysis VIVUS, Inc. reports financial results for the quarter ended June 30, 2017. Highlights Summary numbers: Revenues of USD 11.23 million, Net Earnings of USD -13.39 million. Gross margins narrowed from 80.79% to 68.20% compared to the same period last year, operating (EBITDA) margins now -42.20% from -24.58%. Change in operating cash ... Read more (Read more...)

  • Orexigen's (OREX) Contrave Sales Improving on Promotions
    Zacks4 months ago

    Orexigen's (OREX) Contrave Sales Improving on Promotions

    Despite competition, Orexigen Therapeutics' (OREX) obesity drug, Contrave has performed well so far this year driven by the company's promotional strategies.

  • ACCESSWIRE4 months ago

    VIVUS, Aggressive Marketing For Approved Drugs, Milestone for Tacrolimus, Pipeline Analysis

    NEW YORK, NY / ACCESSWIRE / September 8, 2017 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive ...

  • VIVUS Gives Rights to Alvogen in Korea for Anti-Obesity Drug
    Zacks4 months ago

    VIVUS Gives Rights to Alvogen in Korea for Anti-Obesity Drug

    VIVUS, Inc. (VVUS) signed an agreement with Alvogen giving rights to the latter to market anti-obesity drug Qsymia in Korea for the treatment of chronic weight management or weight-related conditions.

  • Marketwired4 months ago

    VIVUS Announces Tacrolimus Receives Orphan Drug Designation in the European Union for the Treatment of Pulmonary Arterial Hypertension

    VIVUS, Inc. , a biopharmaceutical company committed to the development and commercialization of innovative therapies focusing on treatments for patients with serious unmet medical needs, today announced ...

  • Marketwired4 months ago

    VIVUS and Alvogen Announce Marketing Agreement for Qsymia(R) in the Republic of Korea

    VIVUS, Inc. and Alvogen Malta Operations Ltd, today announced an agreement under which Alvogen will market Qsymia® in the Republic of Korea for the treatment of chronic weight...

  • VIVUS (VVUS) Down 19.8% Since Earnings Report: Can It Rebound?
    Zacks5 months ago

    VIVUS (VVUS) Down 19.8% Since Earnings Report: Can It Rebound?

    VIVUS (VVUS) reported earnings about a month ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Marketwired5 months ago

    VIVUS Announces Settlement with Dr. Reddy's Laboratories on Qsymia(R) Patent Litigation

    VIVUS, Inc. announced today that it has entered into a settlement agreement with Dr. Reddy's Laboratories, S.A. and Dr. Reddy's Laboratories, Inc. resolving patent litigation related to Qsymia® (phentermine ...

  • Marketwired5 months ago

    VIVUS to Present at 2017 Wells Fargo Healthcare Conference on September 7, 2017

    VIVUS,Inc. , a biopharmaceutical company committed to the development and commercialization of innovative therapies focusing on treatments for patients with serious unmet medical needs, today announced ...

  • ACCESSWIRE5 months ago

    Vivus Pipeline Review, Analysis and Potential Catalysts

    NEW YORK, NY / ACCESSWIRE / August 10, 2017 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive ...

  • VIVUS (VVUS) Q2 Loss In Line with Estimates, Sales Down Y/Y
    Zacks5 months ago

    VIVUS (VVUS) Q2 Loss In Line with Estimates, Sales Down Y/Y

    VIVUS reported dismal second-quarter results wherein its loss widened from the year-ago period on lower sales.

  • Marketwired6 months ago

    VIVUS Reports Second Quarter 2017 Financial Results

    VIVUS, Inc. , a biopharmaceutical company committed to the development and commercialization of innovative therapies focusing on treatments for patients with serious unmet medical needs, today reported ...

  • VIVUS Settles with Teva on Weight Management Drug Generic
    Zacks6 months ago

    VIVUS Settles with Teva on Weight Management Drug Generic

    VIVUS, Inc. (VVUS) announced that it has entered into a settlement agreement with Teva Pharmaceutical Industries Limited (TEVA), thereby resolving a three-year old patent litigation related to its weight management drug Qsymia.